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Summary The only hope for effective treatment of hepatocellular carcinoma (HCC or 'hepatoma') lies in early diagnosis. Measurement of the
serum alphafetoprotein (AFP) level is potentially a useful screening test. When grossly raised, it is almost diagnostic of HCC. However,
modestly elevated levels may also arise in patients with benign chronic liver disease, and this markedly decreases the test's specificity and
hence its clinical value. In 582 consecutive attendees at an outpatient clinic for people with chronic liver disease, a single blood sample was
taken for analysis of 'total' AFP and the 'hepatoma-specific' AFP isoform. Using ultrasonography as the primary screening method, patients
with AFP levels .50 ng ml-1 were followed up throughout the study or until HCC was diagnosed on the basis ofconventionally defined criteria.
On entry into the study, 53 patients had an AFP concentration 2 50 ng ml-' and the 'hepatoma-specific' AFP isoform was detected in 26 of
these. During an 18-month follow-up period, a diagnosis of HCC was established by conventional methods in 19 (17 'definite' and two
Iprobable') of these 26 patients. In only two cases was there ultrasound evidence of tumour development at the time AFP was first found to be
elevated; in the remainder a diagnosis of HCC, based on ultrasound screening, was established at a median time of 3.6 months (range 1-18
months) after entry into the study. Among those 27 without the 'hepatoma-specific' isoform, one developed a 'definite' HCC and two developed
Iprobable' tumours. With the application of 'hepatoma-specific' AFP, the positive predictive value of the test was 73.1%, compared with only
41.5% using the conventional 'total' AFP test. Application ofthis test forthe 'hepatoma-specific' AFP markedly increases the positive predictive
value of AFP and, in some cases, permits the presence of tumour to be inferred before it could be detected by routine ultrasound examination.
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Measurement of serum alphafetoprotein (AFP) is, together with
imaging of the liver, a widely used form of investigation in the
diagnosis of hepatocellular carcinoma (HCC or 'hepatoma').
About 80% ofcases ofHCC have a level above the upper limit of
the reference range (10 ng ml-1) (Johnson et al, 1978; Johnson and
Williams, 1980; Liaw et al, 1986; Lok and Lai, 1989; Oka et al,
1990, 1994; Curley et al, 1995). A serum concentration of greater
than 500 ng ml-', in a HCC high-incidence area and in a compat-
ible clinical setting, has been considered to be almost diagnostic of
HCC. However, the range between 10 ng ml-' and 500 ng ml-' is a
'grey area' as patients with benign conditions, such as chronic
hepatitis and cirrhosis, frequently have values which fall within
this range (Bloomer et al, 1975; Alpert and Feller, 1978). Even
higher values (of up to 10 000 ng ml-') are occasionally seen
in patients with benign liver disease, particularly in patients who
are HBsAg seropositive (Lee et al, 1991). The problem is
compounded by the fact that in over 80% ofcases this tumour will
develop in patients who already have some form of chronic liver
disease (Kew and Popper, 1984; Johnson and Williams, 1987).
Further, small tumours tend to have levels which often fall within
the 'grey area' (Sawabu and Hattori, 1987). As it is these small
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tumours that are particularly important to detect with a view to
surgical resection, levels within the non-discriminatory range pose
a major practical problem. Thus, while AFP is a useful marker
when levels are markedly elevated, the poor specificity and posi-
tive predictive value (PPV) forHCC at lower levels severely limits
its practical application.
Attempts to improve the specificity and PPV of the test have
been based on differences in carbohydrate structures of AFP of
different origins (Aoyagi et al, 1985, 1993), which have been
detected by differential binding to various lectins, particularly
lentil lectin and concanavalin A. The approach is clearly useful
and several groups have shown that binding to lentil lectin is
significantly higher for serum AFP from HCC sera than from
benign liver diseases, even at low AFP levels (<500 ng ml-')
(Krusius and Ruoslahti, 1982; Taketa et al, 1983; Aoyagi et al,
1984; Buamah et al, 1986; Govindarajan et al, 1987; Du et al,
1991; Sato et al, 1993). However, these approaches have not been
widely assimilated into clinical practice.
Recently, we have developed an alternative approach using
isoelectric focusing (IEF) to detect isoforms of AFP, some of
which appear relatively specific for HCC (Burditt et al, 1994;
Johnson et al, 1995; Ho et al, 1996). We refer to such isoforms as
'hepatoma-specific' AFP. Of particular interest was the prelimi-
nary observation that the test may become positive many months
before the clinical diagnosis ofHCC was established (Burditt et al,
1994). Thus, the aim ofthe present study was to assess the PPV of
a 'hepatoma-specific' AFP test for the detection of malignant
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Figure 1 Isoforms of AFP. Each lane represents IEF of a serum sample from
a single patient. The presence of isoform +11 constitutes a positive
'hepatoma-specific' AFP test. The isoforms -I to -IV are not taken into
consideration for diagnostic purposes. H is the commonest pattern seen in
cases of established HCC. Examples labelled Hi are similar patterns from
the present series and were seen in 80.8% of the cases. Examples H2 are
the less common 'HCC-specific' pattern from the present series and seen in
19.2% of cases. Examples labelled C are the patterns seen in patients who
did not develop HCC
designed to mirror, as closely as possible, a real clinical situation
so as to permit assessment of the time at which the test becomes
positive in relation to the establishment of the diagnosis of HCC
by conventional means.
MATERIALS AND METHODS
Consecutive attendees at an outpatient clinic for those with
chronic liver disease were entered into the study between April
and December 1994 and followed up until December 1995. The
great majority (91%) had hepatitis B virus-related liver disease,
with less than 10% having alcoholic liver disease or other types of
cirrhosis or chronic hepatitis. The patients were otherwise unse-
lected, and their clinical management was not influenced by the
results ofthis study.
For the purpose of the present study, a single blood sample was
taken for AFP analysis on entry into the study, but the clinician was
at liberty to undertake any other investigations considered in the
patient's best interest. Sera were separated and stored at -700C
before assay for 'total' AFP (i.e. the conventional AFP measure-
ment) by a microparticle enzyme immunoassay (MEIA, Abbott
Laboratories, Chicago IL, USA) on the initial sample. The result was
forwarded to the clinician in charge ofthe patient's management.
Limited by the sensitivity of the technique in its present form
(Ho et al, 1996), only patients with 'total' AFP levels of50 ng ml-'
or above were included in the analysis of AFP isoforms by IEF.
Concurrently, these patients were investigated with ultrasonog-
raphy by an experienced radiologist using an ATL ultrasound
system (HDI 3000, Advance Technology Laboratories, Bothwell,
WA, USA), as soon as logistically possible after the initial finding
of a raised AFP concentration and as frequently as deemed neces-
sary by the clinician in charge.
Analysis of AFP by isoelectric focusing
IEF was undertaken using the method ofBurditt et al (1994), with
modifications as previously described. Briefly, protein samples
were focused in 1.5-mm-thick agarose gel of size 100 x 125 mm,
containing 1% agarose (IEF grade type VIII, Sigma), 5% sorbitol,
10% glycerol and 2% ampholytes pH 4.5-5.4 (Pharmalyte,
Pharmacia). Sera with an AFP level greater than 500 ng ml were
diluted to about 500 ng ml for the test. Samples containing
0.1-1.0 ng of AFP in 2 ,ul were applied directly to the gel and
allowed to diffuse into the gel for 10 min. Isoelectric focusing was
done in a flat bed apparatus (model FBE 3000, Pharmacia) at a
constant temperature of 10°C regulated by a refrigerated circula-
tion bath (RCB 500, Hoefer). Initially, focusing was carried out at
1500 V for 30 min followed by 2000 V for 1 h. The proteins were
transferred to nitrocellulose membrane (Hybond-ECL, Amersham)
by blotting for 80 min. The membrane was treated with 2%
skimmed milk (Carnation non-fat milk powder) to block protein
binding sites. Incubation with polyclonal rabbit anti-human AFP
conjugated with horse radish peroxidase (Dako) diluted 1: 200
with Tris-buffered saline (TBS) containing 2% skimmed milk was
carried out at room temperature with shaking for about 100 min.
After washing with TBS, enhanced chemiluminescence detection
system (ECL, Amersham) and Hyperfilm-ECL (Amersham) were
used to make the protein bands visible.
The presence ofa 'band +11' on IEF, using a previously described
nomenclature (Ho et al, 1996) (Figure 1), constituted a positive
'hepatoma-specific' test. The result ofthis analysis was documented
by one of us (SH) without any knowledge of the clinical situation.
The results ofthese investigations were not revealed to the clinician
in charge until the preliminary analysis in October 1995.
To establish a 'gold standard' in order that the diagnostic use of
'hepatoma-specific' AFP and 'total' AFP could be assessed and
compared, conventional criteria for diagnosis of HCC were laid
down. HCC development was classified as 'definite' if there was
histological confirmation or evidence of tumour(s) on ultrasonog-
raphy with either (i) an AFP level steadily rising to> 1000 ng ml
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Figure 2 Patient outcome in relation to AFP levels and presence or absence of a 'hepatoma-specific' band
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Figure 3 Two ultrasound images from the same patient (A) at the time of detection of the 'hepatoma-specific' band (on entry into the study) when the AFP
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Figure 4 Cumulative incidence of HCC with time in the two groups of
patients, i.e. one group of 26 patients with and another group of 27 without
the 'hepatoma-specific' band. Both probable and definite tumours are
included. The curves have a statistically significant difference (P < 0.0001,
log-rank test). , With 'hepatoma-specific' band; --.--, without 'hepatoma-
specific' band
or (ii) the combination of a raised and steadily rising AFP level in
the range 50-500 ng ml-1 together with HBsAg seropositivity.
Ultrasonograms were considered indicative of tumour(s) if they
detected either (1) an hypoechoic mass or hyperechoic - mixed
echoic mass with hypoechoic margin or (2) an ill-defined hyper-
echoic infiltrative lesion with portal vein invasion. If the only
evidence of tumour was ultrasonographic, without criteria (i) or
(ii) above, the tumour was classified as 'probable'.
Sensitivity, specificity and positive and negative predictive
values were calculated according to standard formulae.
RESULTS
Of the 582 patients entered into the study, 53 had a serum concen-
tration ofAFP equal to or greater than 50 ng ml (range 51-413 ng
ml-' in 50 patients; 3940, 3691 and 1132 ng ml', respectively, for
the remaining three patients). Ofthese, 26 were considered to have
a 'hepatoma-specific' band (AFP + II). These included two of the
three patients with the highest AFP levels, i.e. 3940 and 3691 ng
ml-'. This characteristic 'hepatoma-specific' band was absent in
the other 27 patients, including the one with an AFP level of 1132
ng ml' (Figure 2).
All 53 patients (i.e. with AFP > 50 ng ml-') were followed up for
up to 18 months (median 9 months). At the time of analysis, 19
patients had developed HCC (17 'definite' and two 'probable') in
the group exhibiting the 'hepatoma-specific' band. In 15, including
the two patients with AFP levels of 3940 and 3691 ng ml', the
ultrasound examination (undertaken when the AFP concentration
Table 1 Comparison of demographic data between the 26 patients with and the 27 patients without the hepatoma-specific band.
Patients with hepatoma-specific band Patients without hepatoma-specific band
Mean age (years) + s.d. 56+ 12 53+ 12
Sex (M:F) 20:6 23:4
HBsAg-positive cirrhosis 22 22 (+4)a
Alcoholic cirrhosis 1 4
Hepatitis C-positive 3 1
cirrhosis
Serum AFP level (ng ml-') 130.5 (51-3940) 110 (52-1132)
(median and range)
Tumour diameter (cm)b Median 6, range 2.5-13 2.5 and 6
aThese four patients with alcoholic cirrhosis were also HBsAg seropositive. bOne patient in each group had a diffuse tumour which could not be characterized by
a diameter. None of the differences achieve statistical significance.
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was first found to be raised) did not reveal any evidence oftumour
(Figure 3). Indeed, the elapsed time from the sample testing posi-
tive to imaging evidence for HCC was between 1.0 and 18.0
months (median 3.6 months) (Figure 4).
Among those 27 without the 'hepatoma-specific' band, one
patient developed 'definite' HCC and two developed 'probable'
tumours. The one definite tumour arose 18 months after the initial
serum sample was taken. Retrospective analysis ofa serum sample
available at 13 months after entry into the study (i.e. 5 months
before diagnosis of HCC) showed the 'hepatoma-specific' band.
Over the same period, five patients among the 529 with an initial
AFP level below 50 ng mll were found to have developed HCC.
Using as a 'gold standard' the diagnosis of HCC (criteria previ-
ously described), and defining both 'definite' and 'probable' as
true HCC, the alteration in the positive predictive value for total
AFP alone and 'hepatoma-specific' AFP was calculated, and a rise
from 41.5% to 73.1% was determined. Among patients who have
been screened by conventional AFP tests, the usefulness ofadding
a 'hepatoma-specific' AFP test is that ofcorrectly finding 86.4% of
those who develop HCC (sensitivity) and 77.4% of those who do
not (specificity). In other words, by adding the 'hepatoma-specific'
AFP test 73.1% who are thought to develop HCC will do so (posi-
tive predictive value) and 88.8% who are predicted not to develop
HCC will, indeed, not develop HCC (negative predictive value).
The median diameter ofthe tumours detected in the 'hepatoma-
specific' AFP band group was 6 cm, with a range of 2.5-13 cm
(Table 1). Two patients in this group underwent surgical resection
with curative intent. One patient is alive and well 6 months afterthe
operation, the other has died from liver failure in the post-operative
period. Other patients with small tumours either declined surgery
or the appropriate investigations or were unsuitable because of
decompensated cirrhosis. There were no significant differences
between those with and without the 'hepatoma-specific' AFP band
in terms of age, sex, AFP level, type of cirrhosis or, where appro-
priate, tumour size (Table 1).
DISCUSSION
The study was designed to mirror the clinical conditions under
which this new test might expect to be usefully applied. Under such
circumstances, the 'hepatoma-specific' AFP test increased the
positive predictive value of a moderately raised total AFP level
from 41.5% to 73.1%. It is, at least theoretically, possible that the
test might perform even better in clinical practice, in which it could
be applied serially. Thus, in the patient who developed a definite
tumour but did not have a 'hepatoma-specific' band on entry into
the study, we know in retrospect that a band was present at least 5
months before the tumour was ultimately detected by ultrasound.
Furthermore, among those with 'false-positive' results, more cases
of HCC may, conceivably, yet arise. There is also the problem of
the present 'gold standard' in relation to which results are classified
as false positive. Ultrasound examination and other clinical charac-
teristics may prove to be less sensitive than the new test being
investigated. Thus determining a 'false-positive' rate is impossible
if one cannot rule out tumour development below the sensitivity of
the 'gold standard'.
Among those without histological proofofHCC development, we
relied on a steadily rising AFP level and a characteristic ultrasound
scan to act as a second 'gold-standard'. It is important to consider
only steadily rising AFP as isolated and fluctuating AFP levels can
be seen in patients with non-malignant, regenerative nodules
(Colombo et al, 1991). The diagnostic application ofa 'rising trend'
of AFP is particularly important among HBsAg-seropositive
patients in whom there is wide overlap of AFP levels between
patients with HCC and chronic liverdisease (Lee et al, 1991).
The result of this study implies that the new test is likely to be
more sensitive than our 'gold standard' because in 17 of the 19
cases developing tumour, the test was positive before the tumour
was picked up on ultrasound examination. This is not to say that
application of other imaging methods (such as computerized
tomography scan with contrast enhancement, angiography or lipi-
odol) might not have detected a tumour at this early stage.
However, as mentioned previously, our study was designed to
represent current clinical practice. In this situation such expensive
and invasive examinations could not be applied routinely in areas
where the tumour is common. Although it might appear disap-
pointing that only two cases were successfully resected and only
one of these has had long term survival, we would stress that the
result of the 'hepatoma-specific' AFP test was not used at all in
decisions on the management of these cases. Each was managed
on the basis of our routine care and previous clinical experience
using the conventional 'total' AFP. Whether detailed radiological
examination at a time immediate to the test being found positive
will improve the situation, is currently being investigated,
The figures for sensitivity, specificity and positive and negative
predictive values refer to the test of 'hepatoma-specific' AFP as
applied to patients who had AFP levels of50 ng ml or above. It is
well known that 20-30% ofpatients with HCC will have negative
(< 10 ng ml-') or very low (< 50 ng ml') levels ofAFP (Johnson et
al, 1978; Johnson and Williams, 1980; Liaw et al, 1986; Lok and
Lai, 1989; Oka et al, 1990, 1994; Curley et al, 1995). Such patients
would clearly not be detected by the assay until its detection
limit could be extended to below 50 ng ml-' (Ho et al, 1996).
Furthermore, although in this study only 18.5% of the HCC cases
detected had levels below 50 ng ml', this figure may be falsely
low as the low (<50 ng ml-') AFP group were not screened as
actively as those with a raised AFP.
Although the positive predictive value of the total AFP test is
clearly improved when the 'hepatoma-specific' AFP test is applied,
there is no guaranteed return in terms of improved patient outcome.
This aspect of the test's value was not part of the present study.
Development ofa test that implies a tumourbefore there is any ultra-
sound evidence is novel but may, in itself, cause problems. Whether
a positive test indicates that a tumour was developing or, more likely,
it implies the presence ofa small tumour, is as yet unclear.
The possibility that the 'hepatoma-specific' AFP maybe a
surrogate' marker for some other feature such as advanced
cirrhosis, which thereby defines a group ofpatients more likely to
undergo malignant change, is also worthy of consideration. The
simple demographic data in Table 1 do not support the contention
that there is any systematic difference between those with and
those without the specific band, but a more detailed analysis
imputing histological data and tests of liver function may be more
revealing. Such an analysis will form part ofour next study inves-
tigating the clinical, histological and radiographic features ofthose
patients expressing the 'hepatoma-specific' band.
One could envisage three potentially useful roles for the test.
Firstly, the detection of the 'hepatoma-specific' band in a patient
with cirrhosis would prompt careful and more focused attention in
terms of imaging investigations other than ultrasound examina-
tion. Secondly, among cirrhotic patients in whom liver transplanta-
tion is being considered, a positive test might be one important
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factor that would encourage early transplantation. At present, it is
unlikely that any treatment would be initiated without at least
some imaging evidence of tumour development. However, if our
results are confirmed, it is possible that tumours detected ofsuch a
small size might be more amenable to chemotherapy orbiological-
response modifiers than when the tumour is macroscopically
detectable. Thirdly, the three patients with AFP levels above 1000
ng ml-' in the present study and the other two reported previously
(Ho et al, 1996) suggest that the application of this test may be
usefully extended to AFP concentrations above 500 ng ml-' to
cover a greater number ofpatients.
However, there is at present a drawback ofthe test in its present
form. The procedure is based on an analytical approach which,
although extensively used in research laboratories, is not widely
applied in routine diagnostic laboratories. Further, the biochemical
basis of the 'hepatoma-specific' isoform is, as yet, unknown. We
have recently succeeded in purifying the isoform constituting the
specific band +11 by a combination of preparative isoelectric
focusing followed by immunochromatography. Its biochemical
structure is being determined by mass spectroscopy and other
spectroscopic techniques. Such information may lead to the devel-
opment ofmore readily applicable assays.
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